<p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>)（&#34;Halozyme&#34;）今天宣佈選舉 Jim Lang 為其董事會成員。Lang 先生在醫療保健、生命科學、商業服務和數據分析領域擁有超過 30 年的高管領導經驗。</p>
<p>&#34;Jim 在構建和擴展創新醫療保健企業方面擁有豐富的經驗，我們非常高興歡迎他加入 Halozyme 董事會，&#34;首席執行官兼總裁 Helen Torley 博士表示。&#34;他的戰略洞察力和通過併購推動增長的能力將成為我們實施增長戰略、為包括合作伙伴、患者和股東在內的利益相關者創造有意義的新價值的巨大資產。&#34;</p>
<p>最近，Lang 先生擔任 EVERSANA 的首席執行官，建立了全球領先的生命科學行業商業化服務提供商。作為首席執行官，Lang 先生通過收購超過二十家公司推動了公司的增長，並於 2025 年 8 月與 Waltz Health 合併。Lang 先生仍在 EVERSANA 的董事會任職。他還曾擔任 Decision Resources Group（DRG）的首席執行官，在那裏他通過顯著擴展和收購將 DRG 轉變為領先的醫療數據和分析公司。此前，Lang 先生是 Strategic Decision Group 的總裁，擴展了生命科學業務，後來將其出售給 IMS Health（現為 IQVIA）。</p>
<p>Lang 先生目前在臨牀階段生物製藥公司 Biovie, Inc.的董事會任職，擔任審計委員會和提名與公司治理委員會的主席。他還在數字醫療科技公司 OptimizeRx Corporation 的董事會任職，擔任薪酬委員會主席，並作為提名與公司治理委員會的成員。</p>
<p>&#34;我很榮幸加入 Halozyme 的董事會，&#34;Lang 先生表示。&#34;Halozyme 擁有堅實的基礎和引人注目的增長戰略。我期待與領導團隊合作，幫助加速這一增長，併為我們的股東創造更大的價值。&#34;</p>
<p>Lang 先生獲得新罕布什爾大學電氣與計算機工程學士學位，並在達特茅斯學院塔克商學院獲得 MBA 學位。</p>
<p><strong>關於 Halozyme</strong></p>
<p>Halozyme 是一家生物製藥公司，致力於推進顛覆性解決方案，以改善患者體驗和新興及成熟療法的結果。</p>
<p>作為 ENHANZE®藥物遞送技術的創新者，Halozyme 的專有酶 rHuPH20 提供了經過商業驗證的解決方案，促進了注射藥物和液體的皮下遞送，減少了治療負擔，提高了便利性。ENHANZE®通過十種商業化產品影響了超過一百萬患者的生活，覆蓋超過 100 個全球市場，並已授權給包括羅氏、武田製藥、輝瑞、強生、艾伯維、禮來、百時美施貴寶、argenx、ViiV Healthcare、中外製藥、Acumen Pharmaceuticals 和 Merus N.V.等領先的製藥和生物技術公司。</p>
<p>Halozyme 還在開發 Hypercon™，以擴展其藥物遞送技術組合的廣度。Hypercon™是一種創新的微粒技術，預計將為藥物和生物製劑的超濃縮設定新標準，可以減少相同劑量的注射體積，並擴大家庭和醫療提供者管理的機會。Hypercon™的加入增強了我們轉變患者治療體驗的能力，使我們能夠創造和遞送高度濃縮的生物製劑，顯著擴大了可以皮下遞送的治療範圍。Hypercon™技術已授權給包括強生、禮來和 argenx 等領先的生物製藥合作伙伴。</p>
<p>Halozyme 還開發、製造和商業化藥物 - 設備組合產品，使用先進的自動注射器技術，旨在提高便利性、可靠性和耐受性，增強患者的舒適度和依從性。公司擁有兩種專有商業產品 Hylenex®和 XYOSTED®，以及與 Teva Pharmaceuticals 和 Viatris Inc.的子公司 McDermott Laboratories Limited 的合作商業產品和持續開發項目。</p>
<p>Halozyme 總部位於加利福尼亞州聖地亞哥，在新澤西州尤因、明尼蘇達州明尼通卡和馬薩諸塞州波士頓設有辦事處。明尼通卡也是其運營設施的所在地。</p>
<p>欲瞭解更多信息，請訪問 www.halozyme.com，並在 LinkedIn 和 Twitter 上與我們聯繫。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿可能包含根據 1995 年《私人證券訴訟改革法案》及其修訂版定義的前瞻性陳述。前瞻性陳述是指非歷史事實的陳述，可能包括預測和估計及其基本假設，關於未來財務結果、事件、運營、服務、產品開發和潛力的計劃、目標、意圖和期望的陳述，以及關於 Halozyme 業務未來表現和增長的陳述。前瞻性陳述通常通過 “預計”、“預期”、“相信”、“打算”、“估計”、“計劃”、“將會” 等類似表達來識別。儘管 Halozyme 相信這些前瞻性陳述中反映的期望是合理的，但投資者應注意，前瞻性信息和陳述受到各種風險和不確定性的影響，其中許多是難以預測的，並且通常超出 Halozyme 的控制，這可能導致實際結果和發展與前瞻性信息和陳述中表達的內容存在重大差異。實際結果可能因多種因素而與這些前瞻性陳述中的期望存在重大差異。這些可能導致差異的因素在公司最近提交的 10-K 表格年度報告和向證券交易委員會提交的 10-Q 表格季度報告中進行了更詳細的討論。Halozyme 沒有義務更新或修訂任何前瞻性陳述或本文件中包含的任何其他信息。</p>
<p><strong>聯繫方式</strong></p>
<p>Tram Bui</p>
<p>Halozyme</p>
<p>投資者關係與企業傳播副總裁</p>
<p>609-359-3016</p>
<p>tbui@halozyme.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg"/></p>
<p>來源：Halozyme Therapeutics, Inc.</p>

奧洛茲美醫療

<p>Halozyme Therapeutics, Inc. 宣佈選舉 Jim Lang 為其董事會成員。Lang 在醫療保健和生命科學領域擁有超過 30 年的經驗，預計將為公司提供戰略見解並推動增長。他曾擔任 EVERSANA 和 Decision Resources Group 的首席執行官。Lang 表達了對加入 Halozyme 的熱情，旨在加速增長並提升股東價值</p>

<p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>) (&#34;Halozyme&#34;) today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: <strong>HALO</strong>)（&#34;Halozyme&#34;）今天宣佈選舉 Jim Lang 為其董事會成員。Lang 先生在醫療保健、生命科學、商業服務和數據分析領域擁有超過 30 年的高管領導經驗。</p>
</div><p>&#34;Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board,&#34; said Dr. Helen Torley, president and chief executive officer. &#34;His strategic insight and proven ability to drive growth, including through M&amp;A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our stakeholder, including partners, patients, and shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;Jim 在構建和擴展創新醫療保健企業方面擁有豐富的經驗，我們非常高興歡迎他加入 Halozyme 董事會，&#34;首席執行官兼總裁 Helen Torley 博士表示。&#34;他的戰略洞察力和通過併購推動增長的能力將成為我們實施增長戰略、為包括合作伙伴、患者和股東在內的利益相關者創造有意義的新價值的巨大資產。&#34;</p>
</div><p>Most recently, Mr. Lang served as Chief Executive Officer of EVERSANA, building the leading global provider of commercialization services to the life sciences industry. As CEO, Mr. Lang led the company's growth through the acquisition of over twenty companies, culminating in its merger with Waltz Health in August 2025. Mr. Lang remains on EVERSANA's board. He also formerly served as CEO of Decision Resources Group (DRG), where he transformed DRG into a leading healthcare data and analytics firm through significant expansion and acquisitions. Previously, Mr. Lang was President of Strategic Decision Group, where he expanded the life sciences practice and later sold it to IMS Health (now IQVIA).</p>
<div class="lb-trans"><p>最近，Lang 先生擔任 EVERSANA 的首席執行官，建立了全球領先的生命科學行業商業化服務提供商。作為首席執行官，Lang 先生通過收購超過二十家公司推動了公司的增長，並於 2025 年 8 月與 Waltz Health 合併。Lang 先生仍在 EVERSANA 的董事會任職。他還曾擔任 Decision Resources Group（DRG）的首席執行官，在那裏他通過顯著擴展和收購將 DRG 轉變為領先的醫療數據和分析公司。此前，Lang 先生是 Strategic Decision Group 的總裁，擴展了生命科學業務，後來將其出售給 IMS Health（現為 IQVIA）。</p>
</div><p>Mr. Lang currently serves on the board of Biovie, Inc., a clinical-stage biopharmaceutical company, where he chairs both the Audit Committee and the Nominating and Corporate Governance Committee. He also serves on the board of OptimizeRx Corporation, a digital healthcare technology company, acting as chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.</p>
<div class="lb-trans"><p>Lang 先生目前在臨牀階段生物製藥公司 Biovie, Inc.的董事會任職，擔任審計委員會和提名與公司治理委員會的主席。他還在數字醫療科技公司 OptimizeRx Corporation 的董事會任職，擔任薪酬委員會主席，並作為提名與公司治理委員會的成員。</p>
</div><p>&#34;I am honored to join Halozyme's Board of Directors,&#34; said Mr. Lang. &#34;Halozyme has a strong foundation and a compelling strategy for growth. I look forward to working with the leadership team to help accelerate that growth and deliver even greater value to our shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;我很榮幸加入 Halozyme 的董事會，&#34;Lang 先生表示。&#34;Halozyme 擁有堅實的基礎和引人注目的增長戰略。我期待與領導團隊合作，幫助加速這一增長，併為我們的股東創造更大的價值。&#34;</p>
</div><p>Mr. Lang earned his B.S. in in Electrical and Computer Engineering from the University of New Hampshire and his MBA from the Tuck School of Business at Dartmouth.</p>
<div class="lb-trans"><p>Lang 先生獲得新罕布什爾大學電氣與計算機工程學士學位，並在達特茅斯學院塔克商學院獲得 MBA 學位。</p>
</div><p><strong>About Halozyme</strong></p>
<div class="lb-trans"><p><strong>關於 Halozyme</strong></p>
</div><p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.</p>
<div class="lb-trans"><p>Halozyme 是一家生物製藥公司，致力於推進顛覆性解決方案，以改善患者體驗和新興及成熟療法的結果。</p>
</div><p>As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.</p>
<div class="lb-trans"><p>作為 ENHANZE®藥物遞送技術的創新者，Halozyme 的專有酶 rHuPH20 提供了經過商業驗證的解決方案，促進了注射藥物和液體的皮下遞送，減少了治療負擔，提高了便利性。ENHANZE®通過十種商業化產品影響了超過一百萬患者的生活，覆蓋超過 100 個全球市場，並已授權給包括羅氏、武田製藥、輝瑞、強生、艾伯維、禮來、百時美施貴寶、argenx、ViiV Healthcare、中外製藥、Acumen Pharmaceuticals 和 Merus N.V.等領先的製藥和生物技術公司。</p>
</div><p>Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson &amp; Johnson, Eli Lilly, and argenx.</p>
<div class="lb-trans"><p>Halozyme 還在開發 Hypercon™，以擴展其藥物遞送技術組合的廣度。Hypercon™是一種創新的微粒技術，預計將為藥物和生物製劑的超濃縮設定新標準，可以減少相同劑量的注射體積，並擴大家庭和醫療提供者管理的機會。Hypercon™的加入增強了我們轉變患者治療體驗的能力，使我們能夠創造和遞送高度濃縮的生物製劑，顯著擴大了可以皮下遞送的治療範圍。Hypercon™技術已授權給包括強生、禮來和 argenx 等領先的生物製藥合作伙伴。</p>
</div><p>Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.</p>
<div class="lb-trans"><p>Halozyme 還開發、製造和商業化藥物 - 設備組合產品，使用先進的自動注射器技術，旨在提高便利性、可靠性和耐受性，增強患者的舒適度和依從性。公司擁有兩種專有商業產品 Hylenex®和 XYOSTED®，以及與 Teva Pharmaceuticals 和 Viatris Inc.的子公司 McDermott Laboratories Limited 的合作商業產品和持續開發項目。</p>
</div><p>Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.</p>
<div class="lb-trans"><p>Halozyme 總部位於加利福尼亞州聖地亞哥，在新澤西州尤因、明尼蘇達州明尼通卡和馬薩諸塞州波士頓設有辦事處。明尼通卡也是其運營設施的所在地。</p>
</div><p>For more information, visit www.halozyme.com and connect with us on LinkedIn and Twitter.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.halozyme.com，並在 LinkedIn 和 Twitter 上與我們聯繫。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;plans&#34;, &#34;will be&#34; and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.</p>
<div class="lb-trans"><p>本新聞稿可能包含根據 1995 年《私人證券訴訟改革法案》及其修訂版定義的前瞻性陳述。前瞻性陳述是指非歷史事實的陳述，可能包括預測和估計及其基本假設，關於未來財務結果、事件、運營、服務、產品開發和潛力的計劃、目標、意圖和期望的陳述，以及關於 Halozyme 業務未來表現和增長的陳述。前瞻性陳述通常通過 “預計”、“預期”、“相信”、“打算”、“估計”、“計劃”、“將會” 等類似表達來識別。儘管 Halozyme 相信這些前瞻性陳述中反映的期望是合理的，但投資者應注意，前瞻性信息和陳述受到各種風險和不確定性的影響，其中許多是難以預測的，並且通常超出 Halozyme 的控制，這可能導致實際結果和發展與前瞻性信息和陳述中表達的內容存在重大差異。實際結果可能因多種因素而與這些前瞻性陳述中的期望存在重大差異。這些可能導致差異的因素在公司最近提交的 10-K 表格年度報告和向證券交易委員會提交的 10-Q 表格季度報告中進行了更詳細的討論。Halozyme 沒有義務更新或修訂任何前瞻性陳述或本文件中包含的任何其他信息。</p>
</div><p><strong>Contact</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p>Tram Bui</p>
<div class="lb-trans"><p>Tram Bui</p>
</div><p>Halozyme</p>
<div class="lb-trans"><p>Halozyme</p>
</div><p>VP, Investor Relations and Corporate Communications</p>
<div class="lb-trans"><p>投資者關係與企業傳播副總裁</p>
</div><p>609-359-3016</p>
<div class="lb-trans"><p>609-359-3016</p>
</div><p>tbui@halozyme.com</p>
<div class="lb-trans"><p>tbui@halozyme.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg"/></p>
<p>SOURCE Halozyme Therapeutics, Inc.</p>
<div class="lb-trans"><p>來源：Halozyme Therapeutics, Inc.</p>
</div>

吉姆·朗被選為奧洛茲美醫療董事會成員 | HALO 股票新聞